CpxA/R-Controlled Nitroreductase Expression as Target for Combinatorial Therapy against Uropathogens by Promoting Reactive Oxygen Species Generation

Adv Sci (Weinh). 2023 Sep;10(25):e2300938. doi: 10.1002/advs.202300938. Epub 2023 Jul 5.

Abstract

The antibiotic resistances emerged in uropathogens lead to accumulative treatment failure and recurrent episodes of urinary tract infection (UTI), necessitating more innovative therapeutics to curb UTI before systematic infection. In the current study, the combination of amikacin and nitrofurantoin is found to synergistically eradicate Gram-negative uropathogens in vitro and in vivo. The mechanistic analysis demonstrates that the amikacin, as an aminoglycoside, induced bacterial envelope stress by introducing mistranslated proteins, thereby constitutively activating the cpxA/R two-component system (Cpx signaling). The activation of Cpx signaling stimulates the expression of bacterial major nitroreductases (nfsA/nfsB) through soxS/marA regulons. As a result, the CpxA/R-dependent nitroreductases overexpression generates considerable quantity of lethal reactive intermediates via nitroreduction and promotes the prodrug activation of nitrofurantoin. As such, these actions together disrupt the bacterial cellular redox balance with excessively-produced reactive oxygen species (ROS) as "Domino effect", accelerating the clearance of uropathogens. Although aminoglycosides are used as proof-of-principle to elucidate the mechanism, the synergy between nitrofurantoin is generally applicable to other Cpx stimuli. To summarize, this study highlights the potential of aminoglycoside-nitrofurantoin combination to replenish the arsenal against recurrent Gram-negative uropathogens and shed light on the Cpx signaling-controlled nitroreductase as a potential target to manipulate the antibiotic susceptibility.

Keywords: combinatorial therapy; cpx two-component system; nitroreductase; reactive oxygen species; uropathogens.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amikacin / therapeutic use
  • Aminoglycosides / therapeutic use
  • Anti-Bacterial Agents / pharmacology
  • Anti-Bacterial Agents / therapeutic use
  • Escherichia coli / metabolism
  • Escherichia coli Proteins* / metabolism
  • Escherichia coli Proteins* / therapeutic use
  • Humans
  • Nitrofurantoin / pharmacology
  • Nitrofurantoin / therapeutic use
  • Nitroreductases / therapeutic use
  • Protein Kinases / metabolism
  • Reactive Oxygen Species / therapeutic use
  • Urinary Tract Infections* / drug therapy

Substances

  • Nitrofurantoin
  • Reactive Oxygen Species
  • Amikacin
  • Anti-Bacterial Agents
  • Aminoglycosides
  • Nitroreductases
  • CpxA protein, E coli
  • Protein Kinases
  • Escherichia coli Proteins